Connect with us

Hi, what are you looking for?

Jewish Business News

IPOs

Medical Device Maker Endochoice Eyeing $150 Million IPO

Endochoice

Endochoice, a company which produces all manner of medical devices, is planning a NASDAQ IPO for 2015 which it hopes will bring in $100 to $150 Million. The firm merged with Israel’s endoscopic company Peer Medical in 2013.

If all goes according to plan, Endochoice will be left with a valuation of as much as $600 million.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.

After it merged with Peer medical, Sequoia Capital led a $43 million round of financing in the new company which included investments from Mori Arkin and Dr. Uri Geiger’s Accelmed.

Endochoice has not filed a prospectus yet for the IPO and so there is no word as to how many shares will be offered and at what price and terms. Based in Atlanta GA, EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including devices, diagnostics, infection control and endoscopic imaging for specialists treating a wide range of gastrointestinal (GI) diseases.

The company leverages its direct sales organization to serve more than 2, 000 customers in the United States and works with 34 distribution partners world-wide. The Company was founded in 2008 and has developed a proprietary product portfolio, which includes the Full Spectrum Endoscopy System Fuse. The Fuse System is comprised of colonoscopes and gastroscopes with multiple imagers so doctors can see more of the GI tract for diagnosis and treatment. The Fuse colonoscope provides a field of view of 330 degrees versus 170 degrees from traditional endoscopes.

In a recent clinical study Fuse found 76% more polyps than traditional colonoscopes. 2014 marked the fifth consecutive year EndoChoice was recognized as one of the fastest growing companies in the U.S. by Inc. Magazine.

Newsletter



Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

Life-Style Health

Medint’s medical researchers provide data-driven insights to help patients make decisions; It is affordable- hundreds rather than thousands of dollars

Entertainment

The Movie The Professional is what made Natalie Portman a Lolita.

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...